Human Culture Expanded Genetically Modified Autologous T Cells For Cell-Based Gene Therapy. Cells Are Derived From Isolated Blood Of The Patient And Are Transduced With Non-Replicative Self-Inactivating (Sin) Human Immunodeficiency Virus Type 1 (Hiv-1) Based Lentiviral Vector (Lvv) Pseudotyped With The Vesicular Stomatitis Virus Glycoprotein G (Vsv-G) Envelope Protein, And Encoding The C11D5.3 Anti-Tnf Receptor Superfamily Member 17 (Tnfrsf17, Bcma) Single Chain Variable Fragment (Scfv) Cd8/4-1Bb/Cd3Zeta Chimeric Antigen Receptor (Car) Under The Transcriptional Control Of The Myeloproliferative Sarcoma Virus Enhancer, Negative Control Region Deleted, Dl587Rev Primer-Binding Site Substituted (Mnd) Promote
Plasma Cell Myeloma
Explore 475 assets in Plasma Cell Myeloma →Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Memorial Sloan Kettering Cancer Center
Modality
Cell therapy
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
68High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05393804CT.gov A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant | — | Active Not Recruiting | — | — | — |
NCT05032820CT.gov Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma | — | Completed | — | — | — |
NCT04855136CT.gov Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma | — | Terminated | — | — | — |
NCT04196491CT.gov A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) | — | Completed | — | — | — |
NCT03651128CT.gov Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | — | Active Not Recruiting | — | — | — |
NCT03601078CT.gov An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma | — | Completed | — | — | — |
NCT03361748CT.gov Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02658929CT.gov Study of bb2121 in Multiple Myeloma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Plasma Cell Myeloma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Human Culture Expanded Genetically Modified Autologous T Cells For Cell-Based Gene Therapy. Cells Are Derived From Isolated Blood Of The Patient And Are Transduced With Non-Replicative Self-Inactivating (Sin) Human Immunodeficiency Virus Type 1 (Hiv-1) Based Lentiviral Vector (Lvv) Pseudotyped With The Vesicular Stomatitis Virus Glycoprotein G (Vsv-G) Envelope Protein, And Encoding The C11D5.3 Anti-Tnf Receptor Superfamily Member 17 (Tnfrsf17, Bcma) Single Chain Variable Fragment (Scfv) Cd8/4-1Bb/Cd3Zeta Chimeric Antigen Receptor (Car) Under The Transcriptional Control Of The Myeloproliferative Sarcoma Virus Enhancer, Negative Control Region Deleted, Dl587Rev Primer-Binding Site Substituted (Mnd) Promote (this asset) | Memorial Sloan Kettering Cancer Center | P3 | BB · 66 |
| Hyaluronidase Fihj | Massachusetts General Hospital | P4 | BBB |
| Filanesib | PETHEMA Foundation | P2 | BBB |
| Vincristine Sulfate | Roswell Park Cancer Institute | P3 | BBB |
| Cyclosporin A | Seoul National University Hospital | P3 | BBB |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | University of Birmingham | P4 | BBB |
| Epoetin Alfa | Mayo Clinic | P3 | BB |
| Arsenic Trioxide | Duke University | P2 | BB |
| Sorafenib | OHSU Knight Cancer Institute | P2 | BB |
+42 more in the Plasma Cell Myeloma cohort
Other indications for Human Culture Expanded Genetically Modified Autologous T Cells For Cell-Based Gene Therapy. Cells Are Derived From Isolated Blood Of The Patient And Are Transduced With Non-Replicative Self-Inactivating (Sin) Human Immunodeficiency Virus Type 1 (Hiv-1) Based Lentiviral Vector (Lvv) Pseudotyped With The Vesicular Stomatitis Virus Glycoprotein G (Vsv-G) Envelope Protein, And Encoding The C11D5.3 Anti-Tnf Receptor Superfamily Member 17 (Tnfrsf17, Bcma) Single Chain Variable Fragment (Scfv) Cd8/4-1Bb/Cd3Zeta Chimeric Antigen Receptor (Car) Under The Transcriptional Control Of The Myeloproliferative Sarcoma Virus Enhancer, Negative Control Region Deleted, Dl587Rev Primer-Binding Site Substituted (Mnd) Promote
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Large B-Cell Lymphoma | — | P2 | CCC · 51 |
| Acute Lymphoblastic Leukemia | — | P2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Human Culture Expanded Genetically Modified Autologous T Cells For Cell-Based Gene Therapy. Cells Are Derived From Isolated Blood Of The Patient And Are Transduced With Non-Replicative Self-Inactivating (Sin) Human Immunodeficiency Virus Type 1 (Hiv-1) Based Lentiviral Vector (Lvv) Pseudotyped With The Vesicular Stomatitis Virus Glycoprotein G (Vsv-G) Envelope Protein, And Encoding The C11D5.3 Anti-Tnf Receptor Superfamily Member 17 (Tnfrsf17, Bcma) Single Chain Variable Fragment (Scfv) Cd8/4-1Bb/Cd3Zeta Chimeric Antigen Receptor (Car) Under The Transcriptional Control Of The Myeloproliferative Sarcoma Virus Enhancer, Negative Control Region Deleted, Dl587Rev Primer-Binding Site Substituted (Mnd) Promote in Plasma Cell Myeloma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 10, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/human-culture-expanded-genetically-modified-autologous-t-cells-for-cell-based-gene-therapy-cells-are-derived-from-isolated-blood-of-the-patient-and-are-transduced-with-non-replicative-self-inactivating-sin-human-immunodeficiency-virus-type-1-hiv-1-based-lentiviral-vector-lvv-pseudotyped-with-the-vesicular-stomatitis-virus-glycoprotein-g-vsv-g-envelope-protein-and-encoding-the-c11d53-anti-tnf-receptor-superfamily-member-17-tnfrsf17-bcma-single-chain-variable-fragment-scfv-cd84-1bbcd3zeta-chimeric-antigen-receptor-car-under-the-transcriptional-control-of-the-myeloproliferative-sarcoma-virus-enhancer-negative-control-region-deleted-dl587rev-primer-binding-site-substituted-mnd-promote-plasma-cell-myeloma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →